title: Bismuth accumulates in the body during treatment with tripotassium dicitrato bismuthate.
abstract: Bismuth concentration was measured in plasma, dried leucocytes and urine in nine patients before, during and after treatment with tripotassium dicitrato bismuthate (De-Noltab 2 b.d.) for 6 weeks. During treatment there was an 8.5-fold rise in median plasma bismuth concentration (P less than 0.01), a non-significant doubling of leucocyte bismuth content, and a 349-fold rise in 24-h urinary bismuth excretion (P less than 0.01). The significantly increased urinary bismuth excretion continued for at least 3 months after cessation of treatment with tripotassium dicitrato bismuthate, indicating accumulation of bismuth during treatment with this drug.
authors.affiliation: Academic Department of Medicine, Royal Free Hospital School of Medicine, London, UK.
authors.forename: C J
authors.initials: CJ
authors.lastname: Gavey
authors.forename: M L
authors.initials: ML
authors.lastname: Szeto
authors.forename: C U
authors.initials: CU
authors.lastname: Nwokolo
authors.forename: J
authors.initials: J
authors.lastname: Sercombe
authors.forename: R E
authors.initials: RE
authors.lastname: Pounder
mesh_terms: D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D001729:Bismuth / Q000097:blood / Q000378:metabolism* / Q000652:urine; D005260:Female; D006801:Humans; D007962:Leukocytes / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000494:pharmacology*
chemical_list: D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; C002791:bismuth tripotassium dicitrate; D001729:Bismuth